What Is KPV? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. KPV is not FDA-approved for human therapeutic use. Products sold online as KPV, KPV acetate, Lys-Pro-Val, alpha-MSH fragment, oral KPV, topical KPV, injectable KPV, or “research use only” KPV may carry safety, quality, legal, and regulatory risks.
Quick answer
KPV is a tripeptide made of three amino acids: lysine, proline, and valine. It is derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone, also called alpha-MSH. KPV has been studied mostly in cell, animal, and mechanistic research for anti-inflammatory effects, intestinal inflammation, epithelial barrier protection, antimicrobial activity, and wound-healing biology. The strongest evidence is preclinical, especially around inflammation and gut-barrier models. KPV is not FDA-approved, FDA says it has not identified human exposure data for drug products containing KPV administered by any route, and clinical claims for inflammatory bowel disease, wound healing, skin health, autoimmune disease, or “inflammation support” are not established by strong human trials.
Key facts about KPV
| Question | Answer |
|---|---|
| What is KPV? | A tripeptide made of lysine, proline, and valine. |
| Other names | Lys-Pro-Val, L-lysyl-L-prolyl-L-valine, alpha-MSH 11-13, alpha-MSH fragment, KPV acetate. |
| Peptide class | Alpha-MSH-derived tripeptide / melanocortin-related anti-inflammatory research peptide. |
| Main mechanism | Proposed anti-inflammatory effects through melanocortin-related pathways, NF-kB modulation, cytokine reduction, epithelial uptake through PepT1, antimicrobial activity, and barrier-support mechanisms. |
| FDA-approved? | No. KPV is not an FDA-approved drug. |
| Main studied uses | Intestinal inflammation, inflammatory bowel disease models, wound healing, antimicrobial activity, skin inflammation, epithelial barrier biology, and immune-mediated inflammatory disease models. |
| Human evidence level | Very limited. Strong human clinical outcome evidence is lacking. |
| Animal/lab evidence level | Moderate preclinical evidence for anti-inflammatory, intestinal, antimicrobial, and wound-healing mechanisms. |
| Common online claims | “Gut-healing peptide,” “anti-inflammatory peptide,” “IBD peptide,” “leaky gut peptide,” “wound-healing peptide,” “skin health peptide,” “immune-balancing peptide.” |
| Sports status | Not found here as specifically named on the WADA prohibited list; athletes should verify current WADA/Global DRO status before use. |
| Main safety concern | Lack of human exposure data, unknown long-term safety, uncertain route-specific safety, product-quality risks from online products, and overstatement of preclinical evidence. |
What is KPV?
KPV is a three-amino-acid peptide with the sequence lysine-proline-valine. It is the C-terminal tripeptide sequence of alpha-melanocyte-stimulating hormone, also known as alpha-MSH.
Alpha-MSH is a larger peptide involved in pigmentation, inflammation, immune signaling, and melanocortin receptor biology. KPV is much smaller. It is often discussed as the minimal anti-inflammatory fragment of alpha-MSH.
A PubMed review on alpha-MSH and related tripeptides describes alpha-MSH and related tripeptides as having anti-inflammatory and protective effects in experimental systems.
A PMC study on PepT1-mediated KPV uptake describes KPV as a tripeptide, Lys-Pro-Val, with anti-inflammatory properties and studies its role in intestinal inflammation.
The key distinction:
KPV is a biologically interesting alpha-MSH-derived research peptide, not an FDA-approved treatment for inflammation, gut disease, wound healing, or skin conditions.
How does KPV work?
KPV appears to work through several overlapping anti-inflammatory and barrier-related mechanisms.
Research discusses KPV in relation to:
- Alpha-MSH-derived anti-inflammatory signaling
- Reduced inflammatory cytokine activity
- NF-kB pathway modulation
- Intestinal epithelial uptake through PepT1
- Epithelial barrier support
- Reduced intestinal inflammation in experimental models
- Antimicrobial effects
- Wound-healing biology
- Skin and keratinocyte inflammation models
One important gut-related mechanism is PepT1-mediated uptake. PepT1 is an intestinal peptide transporter. In the PMC Gastroenterology study, researchers reported that KPV uptake through PepT1 reduced intestinal inflammation in experimental models.
In plain English:
KPV is studied because it may calm inflammatory signaling while also interacting with epithelial barriers such as the gut lining and skin.
But mechanism is not proof.
A proposed anti-inflammatory or gut-barrier mechanism does not prove that KPV treats Crohn’s disease, ulcerative colitis, IBS, leaky gut, autoimmune disease, eczema, psoriasis, acne, or chronic wounds in humans.
What is KPV used for?
KPV is commonly discussed for inflammation, gut health, wound healing, skin inflammation, immune modulation, and antimicrobial support. These uses differ sharply in evidence quality.
| Use | Evidence level | What is known | What is not known | |---|---|---| | Intestinal inflammation | Preclinical / mechanistic | KPV reduced intestinal inflammation in experimental models and is studied through PepT1 uptake. | Human efficacy for Crohn’s disease, ulcerative colitis, IBS, or “leaky gut” is not established. | | Inflammatory bowel disease models | Preclinical | Animal and cell studies suggest anti-inflammatory gut effects. | KPV is not an FDA-approved IBD medication. | | Wound healing | Preclinical / review-level | Melanocortin peptides and KPV-related fragments are discussed as possible wound-healing candidates. | Human wound-healing benefit is not established by large controlled trials. | | Skin inflammation | Preclinical / mechanistic | Alpha-MSH/KPV-related peptides have anti-inflammatory effects in skin-related research. | It is not FDA-approved for eczema, psoriasis, acne, dermatitis, or rosacea. | | Antimicrobial activity | Preclinical | Alpha-MSH-related peptides have antimicrobial activity in experimental systems. | Human infection-treatment benefit is not established. | | Immune modulation | Mechanistic | KPV is related to alpha-MSH immune-modulating biology. | It is not an approved immune-modulating drug. | | Autoimmune disease | Weak / extrapolated | Online claims are common. | Human autoimmune-disease treatment evidence is lacking. | | General “inflammation support” | Weak / marketing-driven | The anti-inflammatory biology is plausible. | Broad wellness claims are not clinically proven. | | Online research-use KPV | High uncertainty | Sold as oral, topical, nasal, and injectable products. | Quality, sterility, identity, concentration, absorption, and legality may be unknown. |
What does the research show?
Human evidence
The human clinical evidence for KPV as a therapy is very limited.
Most KPV claims come from:
- Cell-culture studies
- Animal studies
- Intestinal inflammation models
- Wound-healing and skin biology reviews
- Alpha-MSH biology
- Vendor claims
- Extrapolation from melanocortin peptide research
The practical interpretation:
KPV should not be treated as clinically proven for gut healing, inflammatory bowel disease, wound healing, skin conditions, autoimmune disease, or systemic inflammation.
Intestinal inflammation and gut-barrier evidence
The best-known KPV research is in intestinal inflammation.
A PMC study titled “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation” reported that KPV is taken up by PepT1 and reduced intestinal inflammation in experimental models.
This supports a narrow claim:
KPV has preclinical evidence for anti-inflammatory effects in intestinal models.
It does not prove that oral KPV treats Crohn’s disease, ulcerative colitis, IBS, leaky gut, or food intolerance in humans.
Alpha-MSH and anti-inflammatory peptide evidence
KPV comes from alpha-MSH, and alpha-MSH-related peptides have been studied for anti-inflammatory biology.
A PubMed review on alpha-MSH and related tripeptides states that alpha-MSH has potent protective and anti-inflammatory effects and discusses related tripeptides as future therapeutic candidates for immune-mediated inflammatory diseases.
A PMC review describes alpha-MSH-related peptides as a potential new class of anti-inflammatory and immunomodulating drugs.
The practical interpretation:
KPV is scientifically plausible as an anti-inflammatory peptide, but plausible biology is not the same as approved clinical utility.
Wound-healing and skin evidence
KPV and related melanocortin peptides are also discussed in wound-healing and skin-inflammation research.
A PubMed review on melanocortin peptides and wounds states that truncated alpha-MSH peptides such as KPV have anti-inflammatory effects and lack the pigment-inducing activity of alpha-MSH, and discusses their possible future role in cutaneous wounds and skin ulcers.
This supports the idea that KPV is interesting for skin and wound research.
It does not prove that topical or injectable KPV heals wounds, treats eczema, treats psoriasis, improves acne, or reduces scars in humans.
Antimicrobial evidence
Alpha-MSH-related peptides have antimicrobial activity in experimental systems.
A PubMed study on antimicrobial effects of alpha-MSH peptides reported antimicrobial effects and discussed the possibility that peptides combining anti-inflammatory and antimicrobial effects could be useful in disorders where infection and inflammation coexist.
The practical interpretation:
Antimicrobial activity in experimental systems does not make KPV an antibiotic, antifungal, infection treatment, or wound-infection therapy.
FDA safety and compounding context
FDA has specifically addressed KPV in the compounding-risk context.
The FDA page on certain bulk drug substances that may present significant safety risks states that FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration and lacks important information regarding safety issues raised by KPV, including whether it would cause harm if administered to humans.
FDA also announced that its Pharmacy Compounding Advisory Committee will discuss KPV-related bulk drug substances, including KPV free base and KPV acetate, for possible inclusion on the 503A bulks list, with wound healing and inflammatory conditions listed as the uses evaluated.
The practical interpretation:
KPV is not FDA-approved, and FDA has flagged a major human-safety evidence gap.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “KPV is Lys-Pro-Val.” | Supported | KPV is the tripeptide lysine-proline-valine. |
| “KPV is derived from alpha-MSH.” | Supported | KPV is the C-terminal tripeptide of alpha-MSH. |
| “KPV has anti-inflammatory effects.” | Supported preclinically | Cell, animal, and mechanistic studies support anti-inflammatory activity. |
| “KPV reduces intestinal inflammation.” | Supported preclinically | PepT1-mediated uptake studies support intestinal anti-inflammatory effects in models. |
| “KPV heals leaky gut.” | Not established | This is a common online claim, but human clinical evidence is lacking. |
| “KPV treats Crohn’s disease or ulcerative colitis.” | Not established | KPV is not an FDA-approved IBD medication. |
| “KPV heals wounds.” | Not established clinically | Wound-healing research is promising but mostly preclinical or review-level. |
| “KPV treats skin conditions.” | Not established | It is not approved for eczema, psoriasis, acne, rosacea, or dermatitis. |
| “KPV is antimicrobial.” | Supported preclinically | Alpha-MSH-related peptides have antimicrobial activity in experimental systems. |
| “KPV is FDA-approved.” | False | KPV is not FDA-approved. |
| “KPV is safe because it is only three amino acids.” | False | Small size does not prove route-specific human safety. FDA says human exposure data are lacking. |
| “Research-use KPV is clinically proven.” | False | Research-use products are not FDA-approved consumer therapeutic products. |
Is KPV FDA-approved?
No. KPV is not FDA-approved.
There is no FDA-approved KPV product for inflammatory bowel disease, Crohn’s disease, ulcerative colitis, IBS, leaky gut, wound healing, skin inflammation, eczema, psoriasis, acne, immune modulation, or systemic inflammation.
The FDA states that it has not identified human exposure data on drug products containing KPV administered by any route and lacks important safety information regarding whether KPV would cause harm if administered to humans.
The key distinction:
KPV is an experimental anti-inflammatory research peptide, not an FDA-approved medication.
Is KPV legal?
KPV’s legal status depends on product type, intended use, route, jurisdiction, and how it is sold.
The practical answer is simple:
KPV is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic use.
Some sellers market KPV as a research peptide, oral gut-health peptide, topical skin peptide, nasal peptide, or injectable peptide. That does not make it safe, approved, legal, or appropriate for consumer use.
The blunt version:
Buying “research use only” KPV online is not the same as receiving an FDA-approved prescription medication from a legitimate pharmacy.
Is KPV banned in sports?
I did not find KPV specifically named on the WADA prohibited list in the sources reviewed here.
However, athletes should be careful for several reasons:
- Peptide products can be contaminated or mislabeled.
- Anti-doping status can change.
- Unapproved pharmacologic substances can create risk depending on classification, route, or accompanying ingredients.
- Online peptide products may contain substances other than what is listed on the label.
The WADA Prohibited List and USADA prohibited-list guidance should be checked directly before use.
The practical advice:
Athletes should verify KPV through Global DRO, WADA, or USADA before using it and should avoid unapproved online peptide products.
Safety and side effects
KPV should not be treated as risk-free.
Possible or theoretical concerns include:
- Injection-site reactions for injectable products
- Nasal irritation for nasal products
- Skin irritation for topical products
- Gastrointestinal discomfort for oral products
- Immune-system effects
- Unknown long-term safety
- Unknown route-specific safety
- Unknown interaction risk with anti-inflammatory, immune-modulating, or biologic drugs
- Product-quality and sterility risks from online sources
- Mislabeling or incorrect concentration
- Contamination risk
- Unknown absorption and exposure depending on formulation
The biggest safety issue is uncertainty.
FDA says it has not identified human exposure data for drug products containing KPV administered by any route and lacks important safety information about whether KPV would cause harm if administered to humans.
A serious evaluation of KPV should separate controlled laboratory research from online peptide-market claims.
KPV vs similar peptides and drugs
| Compound | Category | Main difference |
|---|---|---|
| KPV | Alpha-MSH-derived tripeptide | Studied for anti-inflammatory, intestinal, antimicrobial, and wound-healing biology. |
| Alpha-MSH | Melanocortin peptide | Larger parent peptide involved in pigmentation, inflammation, and melanocortin signaling. |
| Melanotan II | Melanocortin agonist | Unapproved tanning peptide with broader melanocortin effects and major safety concerns. |
| Afamelanotide | Melanocortin analog | FDA-approved for erythropoietic protoporphyria, not the same as KPV. |
| BPC-157 | Experimental repair peptide | Different peptide, commonly marketed for gut and wound healing, not alpha-MSH-derived. |
| TB-500 | Thymosin beta-4 fragment-like peptide | Repair and wound-healing research peptide, not an alpha-MSH fragment. |
| LL-37 | Antimicrobial peptide | Innate immune antimicrobial peptide, different mechanism and risk profile. |
| GHK-Cu | Copper peptide | Skin, collagen, and wound-healing research, not alpha-MSH-derived. |
| Corticosteroids | Anti-inflammatory drugs | FDA-approved examples exist for many inflammatory conditions, but different mechanism and risk profile. |
| Biologic IBD drugs | Immune-targeting medications | Approved therapies for Crohn’s disease and ulcerative colitis, not comparable to research-use KPV. |
The key distinction:
KPV belongs in the alpha-MSH-derived anti-inflammatory research peptide category. It is not a GLP-1 drug, growth hormone peptide, tanning peptide, approved IBD drug, or generic supplement.
Why is KPV sold as “research use only”?
Some online sellers use “research use only” language to sell KPV outside normal drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Laboratory KPV | Research peptide used in controlled experimental settings. |
| FDA-approved KPV | Does not currently exist. |
| Compounded KPV | Under FDA review in the 503A bulks context, but not the same as an FDA-approved finished drug. |
| Research-use KPV | Not an FDA-approved consumer therapeutic product. |
| Online oral/topical/injectable KPV | Higher risk for identity, purity, sterility, concentration, absorption, and safety problems. |
How to evaluate KPV claims online
| Claim | What to verify |
|---|---|
| “FDA-approved KPV” | False. KPV is not FDA-approved. |
| “Clinically proven gut-healing peptide” | Look for controlled human trials, not only cell or animal studies. |
| “Treats Crohn’s or ulcerative colitis” | Not established. KPV is not an approved IBD therapy. |
| “Heals leaky gut” | Marketing claim unless supported by human clinical evidence. |
| “Heals wounds” | Check whether evidence is human outcome data or preclinical wound models. |
| “Treats eczema, psoriasis, acne, or rosacea” | Not FDA-approved and not established by strong human trials. |
| “Antimicrobial peptide” | Preclinical antimicrobial activity does not mean infection treatment. |
| “No side effects because it is only three amino acids” | False. Human route-specific safety is not established. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe for athletes” | Verify through WADA, USADA, or Global DRO before use. |
| “Third-party tested” | Ask for batch-specific HPLC, LC-MS, identity, purity, sterility, endotoxin, microbial, and stability data. |
Bottom line
KPV is a short alpha-MSH-derived tripeptide with interesting anti-inflammatory, intestinal, antimicrobial, and wound-healing biology. The best evidence is preclinical, especially in intestinal inflammation and inflammatory signaling models.
The most defensible conclusion is:
KPV is a promising research peptide, not a proven consumer therapy. It is not FDA-approved, FDA says human exposure data for KPV drug products are lacking, and online claims about gut healing, wound healing, skin repair, autoimmune disease, and inflammation support often go beyond the current evidence.
FAQ
What is KPV?
KPV is a tripeptide made of lysine, proline, and valine. It is derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone, also called alpha-MSH.
What does KPV stand for?
KPV stands for the amino-acid sequence lysine-proline-valine.
What does KPV do?
KPV is studied for anti-inflammatory, gut-barrier, antimicrobial, wound-healing, and epithelial-protection effects. Most evidence is preclinical.
Is KPV FDA-approved?
No. KPV is not FDA-approved for inflammatory bowel disease, wound healing, skin conditions, immune modulation, or any other therapeutic use.
Does KPV help gut inflammation?
Preclinical studies suggest KPV can reduce intestinal inflammation in experimental models. Human clinical evidence for Crohn’s disease, ulcerative colitis, IBS, or leaky gut is not established.
Does KPV heal wounds?
KPV and related melanocortin peptides are studied for wound-healing biology, but strong human clinical evidence is lacking. KPV is not an FDA-approved wound-healing drug.
Is KPV antimicrobial?
Alpha-MSH-related peptides, including KPV-related sequences, have shown antimicrobial activity in experimental systems. This does not make KPV an approved antibiotic or infection treatment.
Is KPV the same as alpha-MSH?
No. KPV is a short tripeptide fragment derived from alpha-MSH. Alpha-MSH is a larger melanocortin peptide with broader biological effects.
Is KPV the same as Melanotan II?
No. KPV is an alpha-MSH-derived tripeptide studied mainly for anti-inflammatory effects. Melanotan II is an unapproved melanocortin agonist used illegally for tanning and has a very different risk profile.
Is KPV safe?
KPV does not have enough human safety data to call it safe for consumer use. FDA says it has not identified human exposure data for KPV drug products administered by any route and lacks important safety information.
Is KPV legal?
KPV is not an FDA-approved drug. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.
Is KPV banned in sports?
I did not find KPV specifically named on the WADA prohibited list in the sources reviewed here. Athletes should verify current status with WADA, USADA, or Global DRO before use.
Why do sellers call KPV “research use only”?
Sellers often use “research use only” language because KPV is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with KPV?
The biggest risks are using an unapproved peptide without adequate human safety data, relying on preclinical research instead of human clinical evidence, and buying online products with uncertain identity, purity, sterility, concentration, absorption, and safety.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting
- FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- PMC: PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
- PubMed: Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides
- Oxford Academic: Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides
- PMC: Alpha-MSH related peptides, a new class of anti-inflammatory and immunomodulating drugs
- PubMed: Are melanocortin peptides future therapeutics for cutaneous wounds and skin ulcers?
- PubMed: Dissection of the anti-inflammatory effect of MSH 11-13 KPV
- PubMed: Antimicrobial effects of alpha-MSH peptides
- PMC: Alpha-MSH, An Emerging Anti-Inflammatory Antimicrobial Peptide
- PMC: Antifibrotic and Anti-Inflammatory Actions of Alpha-MSH
- WADA: Prohibited List
- USADA: WADA Prohibited List Guidance
Frequently asked questions
What is KPV?
KPV is a tripeptide made of lysine, proline, and valine. It is derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone, also called alpha-MSH.
What does KPV stand for?
KPV stands for the amino-acid sequence lysine-proline-valine.
Is KPV FDA-approved?
No. KPV is not FDA-approved for inflammatory bowel disease, wound healing, skin conditions, immune modulation, or any other therapeutic use.
Does KPV help gut inflammation?
Preclinical studies suggest KPV can reduce intestinal inflammation in experimental models. Human clinical evidence for Crohn’s disease, ulcerative colitis, IBS, or leaky gut is not established.
Does KPV heal wounds?
KPV and related melanocortin peptides are studied for wound-healing biology, but strong human clinical evidence is lacking. KPV is not an FDA-approved wound-healing drug.
Is KPV antimicrobial?
Alpha-MSH-related peptides, including KPV-related sequences, have shown antimicrobial activity in experimental systems. This does not make KPV an approved antibiotic or infection treatment.
Is KPV the same as alpha-MSH?
No. KPV is a short tripeptide fragment derived from alpha-MSH. Alpha-MSH is a larger melanocortin peptide with broader biological effects.
Is KPV safe?
KPV does not have enough human safety data to call it safe for consumer use. FDA says it has not identified human exposure data for KPV drug products administered by any route and lacks important safety information.
Is KPV banned in sports?
No official WADA source was found here specifically naming KPV as prohibited. Athletes should verify current status with WADA, USADA, or Global DRO before use.
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]WADA: Prohibited List
Anti Doping
- [14]USADA: WADA Prohibited List Guidance
Anti Doping
Last updated May 9, 2026